Patient P-01463
Therapy response
Unstable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
83%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 50 GI-04 recommended — GI Support Protocol GI-04
- Day 51 Patient accepted — Started GI-04 in the companion
- Day 52 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 59 No meaningful change — GI Support Protocol GI-04
- Day 59 ME-01 recommended — Monitoring Escalation ME-01
- Day 60 Patient accepted — Started ME-01 in the companion
- Day 63 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 52.
Primary contributors, last 14 days
- GI instability-9
- Inflammatory activity-7
- Toxicity+4
- Nutritional resilience+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- GI Support Protocol GI-04Day 50Result: no meaningful change
- Monitoring Escalation ME-01Day 59Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
76%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 81% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 33/100
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 65
- Autonomic recovery ↑45
- WearableResting HR 77 bpm
- Wearable3,359 steps/day
- Mucosal barrier integrity ↓20
- Daily logGI symptom score 71 and rising
- Drug metabolism and exposure ↑20
- BloodToxicity index 55
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 1.9 · butyrate capacity 33/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 41 ms
- Sleep
- 6.4 h
- Steps
- 4,536
- Resting HR
- 78 bpm
Daily log: GI score 71, nutritional resilience 30, adherence 42.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01897 | 66% | S14 | ME-01 | improved | 43 |
| P-01572 | 64% | S14 | GI-04 | worsened | 41 |
| P-01762 | 64% | S14 | NP-02 | no change | 40 |
| P-01830 | 60% | S14 | — | — | 44 |
| P-01841 | 60% | S14 | — | — | 48 |
| P-01582 | 59% | S14 | GI-04 | no change | 45 |
| P-01721 | 58% | S14 | — | — | 37 |
| P-01751 | 55% | S14 | ME-01 | improved | 48 |
| P-01612 | 54% | S14 | ME-01 | improved | 51 |
| P-01646 | 54% | S14 | GI-04 | no change | 42 |
| P-01605 | 53% | S14 | ME-01 | improved | 41 |
| P-01656 | 53% | S14 | ME-01 | improved | 41 |